Spots Global Cancer Trial Database for A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
Official Title: A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
Study ID: NCT05949749
Conditions
Interventions
Study Description
Brief Summary: Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Contact Details
Name: Xiao-Ming Huang, M.D.
Affiliation: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
